Qiagen (NYSE:QGEN) Shares Sold by Aviva PLC

Aviva PLC decreased its position in shares of Qiagen (NYSE:QGEN – Get Rating) by 89.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 859,410 shares of the company’s stock after selling 7,219,116 shares during the quarter. Aviva PLC’s holdings in Qiagen were worth $47,898,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of QGEN. Massachusetts Financial Services Co. MA increased its holdings in shares of Qiagen by 3.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 20,527,900 shares of the company’s stock worth $1,060,882,000 after buying an additional 765,090 shares during the last quarter. Capital World Investors boosted its stake in shares of Qiagen by 5.1% during the 3rd quarter. Capital World Investors now owns 6,468,766 shares of the company’s stock valued at $334,307,000 after buying an additional 311,414 shares during the last quarter. BlackRock Inc. lifted its stake in Qiagen by 25.6% during the third quarter. BlackRock Inc. now owns 6,056,924 shares of the company’s stock worth $313,022,000 after purchasing an additional 1,233,483 shares during the last quarter. Schroder Investment Management Group lifted its stake in Qiagen by 1,620.3% during the third quarter. Schroder Investment Management Group now owns 3,616,946 shares of the company’s stock worth $162,003,000 after purchasing an additional 3,406,695 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its position in Qiagen by 57.9% in the third quarter. Goldman Sachs Group Inc. now owns 2,693,872 shares of the company’s stock worth $139,219,000 after buying an additional 988,233 shares during the period. 55.85% of the stock is currently owned by hedge funds and other institutional investors.

QGEN has been the topic of a number of research analyst reports. DZ Bank raised Qiagen from a “hold” rating to a “buy” rating in a report on Monday, January 17th. Zacks Investment Research raised shares of Qiagen from a “hold” rating to a “buy” rating and set a $49.00 target price for the company in a research note on Friday, April 22nd. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $52.92.

Shares of NYSE QGEN traded up $0.03 during mid-day trading on Tuesday, hitting $44.92. The company’s stock had a trading volume of 24,292 shares, compared to its average volume of 769,641. The company’s fifty day simple moving average is $47.11 and its 200-day simple moving average is $50.52. Qiagen has a one year low of $41.32 and a one year high of $58.00. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of 17.35, a price-to-earnings-growth ratio of 2.15 and a beta of 0.23. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.90 and a quick ratio of 1.58.

Qiagen (NYSE:QGEN – Get Rating) last announced its quarterly earnings results on Tuesday, April 26th. The company reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.71 by $0.09. Qiagen had a net margin of 26.61% and a return on equity of 20.71%. The firm had revenue of $628.39 million for the quarter, compared to analyst estimates of $589.95 million. During the same quarter in the previous year, the firm posted $0.66 earnings per share. On average, sell-side analysts predict that Qiagen will post 2.52 EPS for the current year.

Qiagen Profile (Get Rating)

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.

Featured Stories